Unconventional binding sites and receptors for VIP and related peptides PACAP and PHI/PHM: an update

Peptides. 2007 Sep;28(9):1655-66. doi: 10.1016/j.peptides.2007.04.006. Epub 2007 Apr 19.

Abstract

The 28-amino-acid neuropeptide VIP and related peptides PACAP and PHI/PHM modulate virtually all of the vital functions in the body. These peptides are also commonly recognized as major regulators of cell growth and differentiation. Through their trophic and cytoprotective functions, they appear to play major roles in embryonic development, neurogenesis and the progression of a number of cancer types. These peptides bind to three well-characterized subtypes of G-protein coupled receptors: VPAC1 and VPAC2 share a common high affinity in the nanomolar range for VIP and PACAP; a third receptor type, PAC1, has been characterized for its high affinity for PACAP but its low affinity for VIP. Complex effects and pharmacological behaviors of these peptides suggest that multiple subtypes of binding sites may cooperate to mediate their function in target cells and tissues. In this complex response, some of these binding sites correspond to the definition of the conventional receptors cited above, while others display unexpected pharmacological and functional properties. Here we present potential clues that may lead investigators to further characterize the molecular nature and functions of these atypical binding species.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Binding Sites
  • Binding, Competitive
  • Humans
  • Peptide PHI / metabolism
  • Receptors, Peptide / metabolism*
  • Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide / metabolism*
  • Receptors, Vasoactive Intestinal Polypeptide, Type I / metabolism*

Substances

  • PHI peptide receptor
  • Peptide PHI
  • Receptors, Peptide
  • Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide
  • Receptors, Vasoactive Intestinal Polypeptide, Type I